To advance highly-differentiated biologics into clinical development and eventually to market, we have forged partnerships with pharmaceutical companies, foundations, academic groups and government organizations with critical therapeutic area expertise and resources. This multi-pronged approach has accelerated the application of our technology across oncology and orphan diseases.
Investors
